Table 2.
Comparison of the some outcomes between the malignant and benign group
| Malignant group (n = 8) | Benign group (n = 55) | P value | All (n = 89) | |
|---|---|---|---|---|
| Age (mean-SD), years | 62.6±4.1 | 59.8±8.4 | *P > 0.05 | 60.1±8.0 |
| SUVmax (mean-SD) | 4.7±2.3 | 4.0±1.0 | *P > 0.05 | 4.1±1.2 |
| PSA level (mean-SD) ng/mL | 47.6±24.4 | 2.3±1.6 | *P < 0.05 | 8.1±17.3 |
| Gleason score (6/7/≥ 8) | 1/4/3 | - | - | 1/4/3 |
| FDG uptake pattern (focal/diffuse) | 7/1 | 46/9 | **P > 0.05 | 53/10 |
| FDG uptake location (peripheral/other (central-both)) | 6/0-1 | 12/28-6 | **P < 0.05 | 18/28-7 |
FDG, fluorodeoxyglucose; PSA, prostate-specific antigen; SUVmax, maximum standardised uptake value; SD, standart deviation;
*
P, according to independent t-test;
**
P, according to the fisher’s exact test.